- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07887464
Clinical, Functional, and Therapeutic Characterization of Women With Urinary Incontinence and Analysis of Factors Associated With Treatment Response (XINE-IA)
Clinical, Functional, and Therapeutic Characterization of Women With Urinary Incontinence and Analysis of Factors Associated With Treatment Response: A Retrospective Observational Study in a Specialized Pelvic Floor Clinic
The goal of this observational retrospective study is to characterize women with urinary incontinence and to identify factors associated with their response to treatment using artificial intelligence models.
The main questions it aims to answer are:
What are the clinical, functional, and therapeutic characteristics of women with urinary incontinence? Which clinical, functional, and lifestyle factors are associated with response to treatment? Can artificial intelligence models identify patterns and factors associated with treatment response?
Researchers will analyze data from women with urinary incontinence collected during routine clinical care at a specialized pelvic floor clinic. The study will combine clinical information from medical records, measurements obtained from clinical assessment instruments, and daily-life data collected using wearable devices such as activity bracelets. Artificial intelligence and machine learning models will be applied to these data to characterize participants and identify factors associated with treatment response.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Javier Pereira, computer science
- Numéro de téléphone: +34 881 01 55 21
- E-mail: javier.pereira@udc.es
Lieux d'étude
-
-
La Coruña
-
A Coruña, La Coruña, Espagne, 15009
- Clínica Cobian
-
Contact:
- Fernando Cobian Sanchez, Ginecologist
- Numéro de téléphone: 981 14 29 29
- E-mail: info@clinicacobian.es
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Women aged 18 years or older with a diagnosis of urinary incontinence who receive routine care at the Clínica Cobián. Participants will provide clinical, functional, therapeutic, questionnaire, and daily-life data, including information collected through wearable devices, for the development and evaluation of an artificial intelligence-based clinical decision support model.
La description
Inclusion Criteria:
- Women aged 18 years or older.
- Diagnosis of urinary incontinence (stress, urgency, or mixed urinary incontinence).
- Patients attending the Clínica Cobián.
- Willingness to participate in follow-up and complete the required patient-reported outcome measures (PROMs).
Exclusion Criteria:
- Inability to provide informed consent.
- Severe diseases or clinical conditions that, in the investigator's judgment, may interfere with participation in the study or interpretation of the results.
Neurological Disorders (Causes of Neurogenic Bladder): Conditions affecting the central or peripheral nervous system can substantially alter bladder control; therefore, urinary incontinence may not be attributable to common mechanical or functional causes, such as stress or standard urgency incontinence.
Multiple sclerosis (MS). Advanced Parkinson's disease or parkinsonian syndromes. Traumatic or medical spinal cord injuries (paraplegia or tetraplegia). Recent stroke or stroke with severe cognitive or motor sequelae. Severe diabetic autonomic neuropathy associated with detrusor hypotonia or urinary retention.
Oncological Conditions and Previous Treatments: Pelvic cancer or its treatments may permanently alter pelvic anatomy and bladder tissue function.
Active urinary tract or gynecological cancer (bladder, prostate, urethra, uterus, or cervix).
History of pelvic radiotherapy. Current chemotherapy, due to systemic effects and potential bladder toxicity (such as cyclophosphamide).
Urological and Urogynecological Conditions: Local conditions that may confound the diagnosis of common urinary incontinence or require immediate surgical treatment.
Severe pelvic organ prolapse (POP), stages III or IV according to the POP-Q classification, as it may cause obstruction or overflow incontinence.
Urogenital fistulas (vesicovaginal or urethrovaginal), in which urine leakage is anatomical and continuous.
Urethral diverticula or severe urethral stenosis. Active bladder stones or untreated low-compliance bladder.
Severe or Unstable Systemic Diseases: Conditions that may pose a risk to the participant's health or adherence to the study, or that may produce symptoms that could be confused with urinary incontinence.
Decompensated congestive heart failure (CHF), which may cause marked nocturnal polyuria and edema, interfering with voiding diaries and assessment of nocturia.
Advanced chronic kidney disease (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m² or requiring dialysis).
Uncontrolled diabetes mellitus (HbA1c >8.5% or 9%), due to osmotic polyuria that may mask actual urinary frequency and urgency.
Severe psychiatric disorders or moderate-to-severe cognitive impairment (e.g., Alzheimer's disease) that may prevent valid informed consent or accurate completion of assessment tools, including voiding diaries and quality-of-life questionnaires.
Recent Pelvic Surgery
Recent urogynecological or prostate surgery (generally within 6 or 12 months before screening), such as radical prostatectomy, total hysterectomy, or placement of pelvic mesh or slings, as the tissue may still be undergoing healing and remodeling.
Conditions that may make adequate follow-up by the investigators difficult. Patients who have given birth within one year before study initiation, in order to avoid the influence of recent postpartum changes on pelvic floor musculature and urinary incontinence symptoms.
Patients who underwent prepartum treatment within one year before study initiation.
Concurrent participation in other clinical studies that may interfere with the objectives of the present study.
Withdrawal Criteria
Voluntary withdrawal of informed consent at any time, without the need to provide a reason.
Failure to comply with study procedures to an extent that prevents adequate data collection.
Occurrence of clinical or personal circumstances that, in the investigator's judgment, warrant withdrawal for safety or feasibility reasons.
Decision by the principal investigator for justified reasons related to study conduct.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Women with urinary incontinence
Women with urinary incontinence whose clinical, functional, therapeutic, and daily-life data are analyzed retrospectively. Data include information from medical records, clinical assessment instruments, and wearable devices such as activity bracelets. Artificial intelligence and machine learning models will be applied to these data to identify factors associated with treatment response. |
Development and evaluation of an artificial intelligence-based clinical decision support model for women with urinary incontinence. The model will integrate clinical data obtained during routine care, measurements from clinical assessment instruments, patient-reported information from questionnaires, and daily-life data collected through wearable devices. The model is intended to identify patterns and factors associated with treatment response and to provide information that may support clinicians in the assessment and management of women with urinary incontinence. The study does not assign or modify the treatment received by participants, which is provided as part of routine clinical care. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Severity of urinary incontinence (ICIQ-UI SF score)
Délai: Baseline (V0) through 12 months (V0, V1 at 3 months, V2 at 6 months, V3 at 12 months)
|
Total score on the ICIQ-UI SF (International Consultation on Incontinence Questionnaire - Urinary Incontinence Short Form), range 0-21, with higher scores indicating greater severity. Treatment response will be defined as an improvement ≥2.52 points (MCID). |
Baseline (V0) through 12 months (V0, V1 at 3 months, V2 at 6 months, V3 at 12 months)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Overactive bladder symptoms (ICIQ-OAB)
Délai: V0(Day 1), V1 (3 months), V2 (6 months), V3 (12 months)
|
Score on the ICIQ-OAB questionnaire (8 items), range 0-16; higher scores indicate greater impairment. |
V0(Day 1), V1 (3 months), V2 (6 months), V3 (12 months)
|
|
Incontinence severity - Sandvik Index (ISI)
Délai: V0(Day 1) and V2 (6 months)
|
Score on the Incontinence Severity Index (2 items), range 0-12, classified as mild/moderate/severe/very severe. |
V0(Day 1) and V2 (6 months)
|
|
Lower urinary tract symptom-specific quality of life (ICIQ-LUTSqol)
Délai: V0(Day 1), V1 (3 months), V2 (6 months), V3 (12 months)
|
Score on the ICIQ-LUTSqol questionnaire (19 items), range 19-76; higher scores indicate greater impairment in quality of life. |
V0(Day 1), V1 (3 months), V2 (6 months), V3 (12 months)
|
|
Patient Global Impression of Severity (PGI-S)
Délai: V0 (baseline)
|
Single-item scale (1-4) assessing the patient's global perception of symptom severity. |
V0 (baseline)
|
|
Patient Global Impression of Improvement (PGI-I)
Délai: V1 (3 months), V2 (6 months), V3 (12 months)
|
Single-item scale (1-7) assessing the patient's global perception of improvement relative to baseline. |
V1 (3 months), V2 (6 months), V3 (12 months)
|
|
Sexual function (FSFI)
Délai: V0(Day 1), V1 (3 months), V2 (6 months), V3 (12 months)
|
Female Sexual Function Index (19 items, 6 domains), range 2-36; a cutoff score ≤26.55 indicates female sexual dysfunction. |
V0(Day 1), V1 (3 months), V2 (6 months), V3 (12 months)
|
|
Pelvic floor muscle function (Oxford Scale )
Délai: V0(Day 1) and V2 (6 months)
|
Pelvic floor muscle contraction strength will be assessed by vaginal palpation using the Oxford Scale, ranging from 0 (no contraction) to 5 (strong contraction). The outcome will be reported as the Oxford Scale score. |
V0(Day 1) and V2 (6 months)
|
|
Amount of urine loss (1-hour Pad Test, ICS)
Délai: V0(Day 1) and V2 (6 months)
|
Standardized 1-hour pad test; objective quantification of urine loss in grams. |
V0(Day 1) and V2 (6 months)
|
|
Voiding pattern (3-day Bladder Diary)
Délai: V0(Day 1) and V2 (6 months)
|
Voiding pattern and urinary symptoms will be assessed using a 3-day bladder diary. The recorded variables will include daytime and nighttime voiding frequency, urinary incontinence episodes per 24 hours, urgency episodes, voided urine volume, fluid intake, and pad use. Results will be reported for each recorded variable using the corresponding measurement unit. |
V0(Day 1) and V2 (6 months)
|
|
Treatment satisfaction
Délai: V1(3 months), V2(6 months), V3 (12 months)
|
Proportion of patients reporting satisfaction or high satisfaction with the treatment received, assessed via a satisfaction survey. |
V1(3 months), V2(6 months), V3 (12 months)
|
|
Contextual physical activity variables (wearables)
Délai: Continuous throughout the follow-up period (minimum 7 days)
|
physycal activity via a wearable device with local storage. |
Continuous throughout the follow-up period (minimum 7 days)
|
|
Contextual sleep variables (wearables)
Délai: Continuous throughout the follow-up period (minimum 7 days)
|
sleep duration via a wearable device with local storage. |
Continuous throughout the follow-up period (minimum 7 days)
|
|
Contextual daily heart rate (wearables)
Délai: Continuous throughout the follow-up period (minimum 7 days)
|
mean daily heart ratevia a wearable device with local storage. |
Continuous throughout the follow-up period (minimum 7 days)
|
|
Pelvic floor muscle function (PERFECT protocol)
Délai: Baseline (Day 1) and 6 months
|
Pelvic floor muscle function will be assessed using the PERFECT protocol, including power, endurance, number of repetitions, number of fast contractions, co-contraction, and timing. Each component will be recorded according to the standardized PERFECT protocol. |
Baseline (Day 1) and 6 months
|
|
Bladder symptoms assessed by the ICIQ-Bladder Diary (ICIQ-BD)
Délai: Baseline (Day 1) and 6 months
|
Bladder symptoms will be assessed using the International Consultation on Incontinence Questionnaire-Bladder Diary (ICIQ-BD). The outcome will be reported according to the scoring and variables specified by the ICIQ-BD instrument. |
Baseline (Day 1) and 6 months
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies urogénitales masculines
- Maladies urologiques
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Troubles urinaires
- Symptômes des voies urinaires inférieures
- Manifestations urologiques
- Conditions pathologiques, signes et symptômes
- Signes et symptômes
- Incontinence urinaire
Autres numéros d'identification d'étude
- 2026/271
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .